Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Recruiting now · Phase 1
Conditions studied: Cancer Metastatic, Metastatic Solid Tumor
In brief
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Key facts
- Study ID
- NCT05232409
- Run by
- Valley Health System
- People needed
- 72
- Starts
- 2022-04-17
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-06-05
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Valley Hospital-Luckow Pavilion — Paramus, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.